Mallinckrodt to Present Open-Label Results from Phase 4 ActharŽ Gel (Repository Corticotropin Injection) Clinical Trial in Patients with Rheumatoid Arthritis at Annual European Congress of Rheumatology (EULAR 2019)
Font : A-A+
-- Company also announces completion of controlled, double-blind, randomized phase (n=154; open-label phase, n=259) of multicenter study -
Post your Comments
Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer